Gilead Sciences

Gilead Announces Senior Management Change

Retrieved on: 
Tuesday, March 5, 2019
Health, Biotechnology, Hospitals, Pharmaceutical, Biotechnology, Gilead Sciences, Life sciences, Gilead, Bible

Dr. Riva will remain at Gilead through the end of the month.

Key Points: 
  • Dr. Riva will remain at Gilead through the end of the month.
  • Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutics Area Head.
  • Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
  • For more information onGilead Sciences, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12

Retrieved on: 
Tuesday, March 5, 2019
Health, Biotechnology, Hospitals, Pharmaceutical, Biotechnology, Gilead Sciences, Gilead, Life sciences, Bible

The audio portion of the fireside chat will be accessible live through the companys Investors page at www.gilead.com/investors .

Key Points: 
  • The audio portion of the fireside chat will be accessible live through the companys Investors page at www.gilead.com/investors .
  • Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
  • Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
  • For more information on Gilead Sciences, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Analysis & Outlook 2019-2023 with Profiles of Novartis International, Bluebird Bio, Celgene and Gilead Sciences - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2019
Health, Oncology, Life sciences, Biotechnology, Health, Cancer treatments, Gene therapy, Bristol-Myers Squibb, Celgene, Summit, New Jersey, Chimeric antigen receptor T cell, Novartis, Gilead Sciences

The "Global Chimeric Antigen Receptor (CAR) T-Cell Therapy: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chimeric Antigen Receptor (CAR) T-Cell Therapy: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.
  • Global CAR-T Cell Market: Industry Analysis & Outlook (2019-2023) provides extensive research and detailed analysis of the present market along with future outlook.
  • The report discusses the major growth drivers and challenges of the market, covering The United States, Europe, and Japan region along with the global market.
  • The report profiles the key players of the market including Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.

Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend

Retrieved on: 
Monday, February 4, 2019
Health, Biotechnology, Hospitals, Medical devices, Pharmaceutical, Medical Supplies, Biotechnology, Gilead Sciences, Life sciences, Dividend, Gilead, Industries

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared an increase of 11% in the companys quarterly cash dividend, beginning in the first quarter of 2019.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared an increase of 11% in the companys quarterly cash dividend, beginning in the first quarter of 2019.
  • The increase will result in a quarterly dividend of $0.63 per share of common stock.
  • The dividend is payable on March 28, 2019, to stockholders of record at the close of business on March 15, 2019.
  • For more information on Gilead Sciences, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Atripla - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 1, 2019
Professional services, Consulting, Gilead Sciences, Hepatotoxins, Bristol-Myers Squibb, RTT, Fixed dose combination, Efavirenz/emtricitabine/tenofovir, SWOT analysis, Medical specialties

The "Atripla - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atripla - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Atripla Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • In addition to this, the report also provides the SWOT analysis for Atripla and emerging therapies in this space.
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Viread - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 1, 2019
Professional services, Consulting, Chemistry, Strategic management, Gilead Sciences, Hepatotoxins, Organic compounds, RTT, Tenofovir disoproxil, Organic chemistry, SWOT analysis, SWOT

The "Viread - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viread - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Viread Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • In addition to this, the report also provides the SWOT analysis for Viread and emerging therapies in this space.
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Cryoport Opens Global Logistics Center in Amsterdam

Retrieved on: 
Wednesday, January 30, 2019
Articles, Life sciences, Biotechnology, Gilead Sciences, Pharmaceutical industry in China, Logistics, Novartis, Schiphol Airport railway station, Janssen Pharmaceutica

IRVINE, Calif., Jan. 30, 2019 /PRNewswire/ --Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today will celebrate the official opening of its most recent Global Logistics Center, based in Amsterdam, The Netherlands.

Key Points: 
  • IRVINE, Calif., Jan. 30, 2019 /PRNewswire/ --Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today will celebrate the official opening of its most recent Global Logistics Center, based in Amsterdam, The Netherlands.
  • The new Global Logistics Center is located at Parellaan 18, 2132 WS Hoofddorp, near the Schiphol Amsterdam Airport, which serves as The Netherland's main aviation hub for international air traffic.
  • Opening this new state-of-the-art Global Logistics Center in Amsterdam strategically adds to Cryoport's global network supporting the distribution of biopharmaceutical products requiring exacting temperature and condition controls.
  • Cryoport clients, including Gilead Sciences, Novartis, Bellicum Pharmaceuticals, Immatics, Janssen Pharmaceuticals, and others, will benefit from Cryoport's new Global Logistics Center.

Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019

Retrieved on: 
Tuesday, January 22, 2019
Health, Biotechnology, Hospitals, Pharmaceutical, Biotechnology, Gilead Sciences, Gilead, Bible, Literature

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.
  • At 4:30 p.m. Eastern Time, Gileads management will host a conference call to discuss the companys financial results for the fourth quarter and full year 2018 and provide a business update.
  • Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
  • For more information on Gilead Sciences, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Fish & Richardson Obtains Denial of Cert at U.S. Supreme Court for Gilead Sciences in Long-Running Patent Battle with Merck Over Hepatitis C Drugs

Retrieved on: 
Thursday, January 10, 2019
Biotechnology, Specialty drugs, Health, Pharmaceutical industry, Gilead Sciences, Hepatitis C, Merck & Co., Sofosbuvir, Merck, Pharmasset

Fish proved post-trial that Merck had forfeited its right to assert its hepatitis C drug patents against Gilead because of litigation and business misconduct constituting unclean hands.

Key Points: 
  • Fish proved post-trial that Merck had forfeited its right to assert its hepatitis C drug patents against Gilead because of litigation and business misconduct constituting unclean hands.
  • Merck filed a petition for certiorari in September 2018, and the case was considered in conference on January 4 before cert was denied on January 7.
  • The case, Gilead Sciences, Inc. v. Merck & Co. Inc. et al.,beganafter Merck requested that Gilead license two patents ('499 and '712).
  • Fish has been representing Gilead for over five years in its worldwide, complex patent battle with Merck and Idenix Pharmaceuticals (now owned by Merck) over Gilead's two blockbuster hepatitis C drugs, Sovaldi and Harvoni.

Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Retrieved on: 
Sunday, January 6, 2019
Health, Biotechnology, Hospitals, Pharmaceutical, Biotechnology, Specialty drugs, Gilead Sciences, Hepatitis, Pharmaceutical industry, Yuhan, Steatohepatitis, Health

Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.KS; Yuhan) today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).

Key Points: 
  • Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.KS; Yuhan) today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
  • Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development.
  • This agreement builds on the companies existing commercial collaboration to support the promotion of Gileads medicines in the Republic of Korea.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.